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Abstract 
Background: In the year 2005, an epidemic of Japanese encephalitis (JE) occurred in the northern states of India. The present study was 
planned to reconfirm the circulation of JE in the area and to assess the trend of the disease to slow down the burden of JE. 
Methodology: Surveillance was conducted to identify patients with acute encephalitis. Blood and cerebrospinal fluid specimens  from 
suspected cases underwent pathological, serological, and demographic investigations. Viral testing for evidence of Japanese encephalitis 
virus (JEV) infection was also performed, either by IgM capture ELISA/RT-PCR or both. To identify circulating JEV strains, RT-PCR, 
sequencing and phylogenetic analysis was performed.  Based on clinical cases reported between 1992 and 2008, the trend of JE infection in 
the state was analyzed to examine the dynamics of infection.  
Results: Our investigations (n = 38) revealed that only 55.3% cases were positive for JE. Pathological examination revealed marked 
pleocytosis in CSF (90  76.9 cells/mm3), and peripheral leucocytosis (64.7  8.86% neutrophils) with mild anemia. Males were more 
susceptible than females with a ratio of 1.63:1 and significant gender difference (P  0.05) was observed in patients below six years. In the 
patient group younger than six years, the rate of infection per million was six-fold higher (P  0.005) in males as compared to females. Our 
phylogenetic study suggests that the circulating strain during the 2005 JE epidemic was close to GP78, and in the future a larger epidemic 
may occur.   
Conclusions: The 2005 JE epidemic was possibly caused by JEV GP78 and it is spreading into newer areas.  The trend of JE suggests that 
the problem in North India is escalating and larger epidemics may occur in the future; therefore, serious steps are necessary to combat JE, 
including the development of more efficient surveillance methods and differential diagnosis.   
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Introduction 
Almost every year, so-called “undiagnosed 
illnesses” invade India and unfailingly claim 
thousands of lives. Viral encephalitis, a major global 
emerging public health problem, is among them. 
Although viruses are the most common cause of 
encephalitis, bacteria, fungus, and parasites may also 
be responsible for infection. In India, although many 
encephalitis outbreaks have been reported since 
1955 [1], several have remained undiagnosed. In the 
absence of a defined cause, these outbreaks were 
tentatively attributed to Reye’s syndrome, dengue,  
chikungunya, Japanese encephalitis (JE) and 
measles. Between July and December 2005, a large 
and severe epidemic of viral encephalitis was seen in 
northern India. The disease gripped Uttar Pradesh,  
 
border areas of Bihar and Nepal. During this interval 
a total of 6097 JE cases with 1,398 deaths were 
reported [2,3]. The case fatality rate (CFR) was 
22.9%. Uttar Pradesh was most affected with 5,737 
JE cases and 1,334 deaths (CFR 23.3%) and Bihar 
experienced 360 cases with 64 deaths (CFR 17.8%) 
[2]. However, the true incidence was much higher, 
as most of the cases remained asymptomatic and 
undiagnosed.  
The majority of the cases during this epidemic 
came from eastern Uttar Pradesh (Gorakhpur and 
adjoining areas), which is the paddy growing “Terai 
area.” Uttar Pradesh (a northern state of India) lies 
between latitudes 24º and 31º north and longitudes 
77º and 84º east (Figure 1) and is surrounded by 
Uttaranchal in the northeast, Haryana and Himachal 
Pradesh in the north, Delhi and Rajasthan in the 
west, Madhya Pradesh in the southwest, 
Chhattisgarh in the south, Bihar in the southeast, and  
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Nepal along the East. After the 2001 census, Uttar 
Pradesh is the most populous state in India, 
accounting for 16.4% of the total population of the 
country. Population density of this state is 689 
persons per square kilometer, while it is 324 persons 
per square kilometer for the country. Children aged 
0 to 6 years make up 18.35% of the population, of 
which 9.58% are male and 8.77% are females, while 
approximately 40% of the total population belongs 
to the 0-12 year age group. The rural population is 
79.22% [4]. There are three distinct seasons: 
Summer (March to June, with temperatures ranging 
from 27.5º-32.5 ºC, with a max 45 ºC); Monsoon 
(July to October, with rainfall of 1,000-2,000 mm in 
the east, and 600-1,000 mm in the west); and Winter 
(November to February, with temperatures ranging 
from 12.5º-17.5 ºC). The entire state has a tropical 
monsoon climate.  
JE is an acute viral zoonotic infection of the 
central nervous system (CNS), which produces 
meningomyelo-encephalitis. It poses a serious public 
health problem with an increasing frequency of 
epidemics and outbreaks in many parts of the Indian 
subcontinent and South East Asian countries over 
the last four decades. Now approaching newer areas 
such as Papua New Guinea and Australia, it has been 
classified as new emerging disease [5,6]. JE virus 
(JEV) is an arthropod-borne flavivirus and is 
transmitted to human beings by Culex 
tritaeniorrhynchus and other related rice field-
breeding mosquitoes of genus Culex. The disease 
commonly affects children and is a major cause of 
acute childhood encephalopathy. JEV or 
antigenically related virus has been identified  
 
 
 
serologically in different parts of India since the 
mid-fifties. Although initial cases of JE were 
reported in the 1950s in India, Uttar Pradesh saw its 
first epidemic in 1978 [7]. Since then, this 
encephalitis has taken more than 10,000 lives in the 
state [8,9]. As in 2005, most of the cases of acute 
encephalitis came from Gorakhpur and adjoining 
areas. In the present study, patients with acute 
encephalitis were enrolled from this area and 
examined for the evidence of JE infection with 
clinicopathological, serological, and demographical 
features. Based on current evidence and historical 
epidemics of JEV in Uttar Pradesh (India), we will 
discuss the current trend of the disease to prepare 
ourselves for the possibility of a future epidemic.   
 
Materials and Methods 
 
Outbreak Surveillance and sample collection 
After approval from the Institutional Review 
Board of the Centre for Cellular and Molecular 
Biology, Hyderabad, surveillance was conducted at 
Gorakhpur and adjoining areas to identify patients 
with acute encephalopathic illness during July to 
November 2005. A patient was suspected to have 
encephalitis if all the following criteria were met: (i) 
a recent history of fever; (ii) cerebrospinal fluid 
(CSF) protein concentration of at least 40 mg per 
deciliter or white blood cell (WBC) count of at least 
5 per cubic millimeter; (iii) no other clinical 
diagnosis; (iv) neurological impairment. Mild and 
acute encephalitis were categorized on the basis of 
severity of symptoms. Mild encephalitis was 
characterized by mild fever and headache, and the 
patient testing positive for JE-ELISA. However, a 
Figure 1.  Japanese encephalitis affected areas of India, 2005. The map of India shows Uttar Pradesh outlined in red, the 
area which was worst affected by JE in 2005 (Map modified and used with permission from Google  Maps, CA, USA). 
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recent history of any one or more symptoms 
including altered sensorium, headache, stiffness of 
the neck, tremors, vomiting, altered mental status, 
seizure, myalgia, abdominal pain and depressed 
level of consciousness with coma and paralysis 
along with fever along with positive testing for JE-
ELISA indicated acute encephalitis. No tests were 
performed for Reye's syndrome, dengue, 
chikungunya or any other flavivirus infections.  A 
total of 38 patients with symptoms of acute 
encephalopathic illness were enrolled for this study 
(Table 1). After the written informed consent of the 
patient/patient’s guardian was obtained, blood and/or 
CSF samples were collected and stored at 20 C. No 
patient had history of JE vaccination. All JE patients 
were examined completely for clinico-pathological 
symptoms as described above, and previous clinical 
history and demographic information about the 
patients were obtained. 
 
Laboratory investigation Blood and/or CSF 
specimens from patients underwent serological and 
viral testing for evidence of arboviral infection by 
IgM-capture ELISA. For every examination, serum 
and/or CSF samples were collected by single aseptic 
venipuncture or lumber puncture respectively. All 
the serum and CSF samples were tested for the 
presence JEV by IgM-capture ELISA (JEV CheX 
IgM ELISA Kit, XCyton Diagnostics Ltd., 
Bangalore, India) according to the manufacturer’s 
instructions. Briefly, CSF and serum samples were 
diluted 10- and 20-fold respectively and 100 µl of 
test CSF/serum samples with appropriate controls 
were incubated in ELISA plates for one hour at 
37ºC. To each well 100 µl of JEV antigen was added 
and incubated at 37ºC for one hour and washed 
again. Next, 100 µl of biotinylated-monoclonal 
antibody was added and incubated for 30 minutes at 
37ºC and 100 µl of streptavidin-peroxidase 
conjugate was added. The plate was kept at room 
temperature for 15 minutes and 100µl of substrate 
was added to each well and the plate was left for 10 
minutes at room temperature. Finally, 100 µl of stop 
solution was added to each well to arrest the 
reaction. The plate was read at 450 nm in an ELISA 
reader (SpectraMax 190, Molecular Devices, 
Sunnyvale, California, USA) within one hour of 
reaction. A positive reaction of the CSF sample 
confirmed JEV infection and a positive reaction of 
the serum sample suggested a recent JEV infection. 
Samples were considered as JE positive if the 
ELISA value was more than 100 ELISA units; 
otherwise, samples were considered as JE negative 
[10] (Table 1). This kit is already evaluated for its 
sensitivity, specificity, and usability against JE 
patient samples by various workers [11,12].  If the 
blood and CSF samples drawn from a patient within 
first five days of fever were found non-reactive, a 
second serum/CSF sample was collected from that 
patient after seven days of the occurrence of the 
fever. Clinical investigations of JE positive patients 
included the following: complete peripheral blood 
examination; blood glucose level; CSF examination 
for appearance with cell count; measurement of 
glucose and protein; bacterial culture; and gram 
staining. 
 
Molecular and Phylogenetic analysis 
Notably, we could also extract viral RNA, 
specifically GP05, from a CSF sample (I.D. 17).  
Viral RNA was isolated using a GF-1 Viral 
RNA/DNA Extraction Kit (Vivantis Inc., California, 
USA) according to the manufacturer’s instructions. 
The full env gene of GP05 was amplified by 
standard reverse-transcriptase polymerase chain 
reaction (RT-PCR). RT-PCR was performed with an 
RT-PCR Kit (Promega, Madison, WI, USA) using 
5’CTGTTGGTCGCTCCGGCTTACAG3’ as the 
forward primer and 5’ 
AGCATGCACATTGGTCGCTAAGAA3’ as the 
reverse primer. Primers were designed against the 
env gene of JEV GP78 (AF075723) as a reference 
sequence by using Gene Tool software (BioTools 
Inc., Edmonton, Canada) and synthesized by 
Bioserve Biotechnologies India Pvt. Ltd., India.  
Briefly, for a 20 µl RT-reaction, 100 mM MgCl2, 
10X RT Buffer, 10mM dNTPs, 0.5 unit RNasin, 2.5 
unit of reverse transcriptase, 15 picomolar reverse 
primer and 200ng viral RNA were added. RT was 
performed at 47°C for one hour.  Second strand 
synthesis was performed by PCR for a 20 µl reaction 
using 10X PCR Buffer (Applied Biosystems, USA), 
37 mM MgCl2 (Applied Biosystems, USA), 5 mM 
dNTP mix (Eppendorf, Germany), 2 pM each of 
forward and reverse primers, 2 units of AmpliTaq 
Gold DNA Polymerase (Applied Biosystems, USA), 
and 1µl of cDNA. Amplification was carried out for 
35 cycles in Eppendorf Mastercycler EP (Eppendorf, 
Germany), each consisting of denaturation at 95 C 
for 30 seconds, annealing at 60 C for 30 seconds,  
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and extension at 72 C for 2 minutes. Pre- 
denaturation and a further extension were performed 
at 95 C for 10 minutes and 72 C for 10 minutes 
respectively. Sequencing of the amplicon was 
performed on an ABI 3130 sequencer (Applied 
Biosystems, USA) with the BigDye Terminator  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
cycle sequencing ready reaction kit with the primers 
mentioned above. Phylogenetic analysis of GP05 
was performed with other known Indian as well as 
Southeast Asian JEV strains considering other 
flaviviruses as outlined. All the sequences were 
retrieved from NCBI (Table 2) and a neighbour- 
 
I.D. Sex Age 
Sample JEV-IgM EU 
Result 
Serum CSF Serum CSF 
1 F 11Y N Y N -2.69 JE  -ve 
2 M 8Y N Y N 3.07 JE –ve 
3 F 10Y N Y N 3.07 JE –ve 
4 M 4Y Y N 699.22 N JE  +ve 
5 F 11Y N Y N 3.46 JE -ve 
6 M 8Y N Y N -0.76 JE –ve 
7 F 8Y Y N 61.47 N JE –ve 
8 F 6Y N Y N -4.46 JE –ve 
9 M 6.3Y N Y N -2.74 JE –ve 
10 M 11Y N Y N 168.04 JE  +ve 
11 M 8Y N Y N 250.51 JE  +ve 
12 M 5Y N Y N 293.12 JE  +ve 
13 F 7Y N Y N 275.25 JE  +ve 
14 F 6Y N Y N 494.84 JE  +ve 
15 F 6Y N Y N 91.75 JE –ve 
16 M 10Y N Y N -0.68 JE –ve 
17 F 8Y N Y N 103.09 JE  +ve 
18 M 4.6Y Y N 499.59 N JE  +ve 
19 F 12Y Y N 416.06 N JE  +ve 
20 M 5Y Y N 6.82 N JE –ve 
21 M 7Y Y N 285.54 N JE  +ve 
22 M 10Y Y N 223.92 N JE  +ve 
23 M 8.6Y Y N 592.8 N JE  +ve 
24 F 8Y Y N 300.34 N JE  +ve 
25 M 6Y Y N 182.19 N JE  +ve 
26 M  Y N 13.7 N JE –ve 
27 F 8Y Y N 167.51 N JE  +ve 
28 F  Y N 46.19 N JE –ve 
29 M  Y N 13.7 N JE –ve 
30 F 9Y Y N 85.88 N JE –ve 
31 M 6Y Y N 534.7 N JE  +ve 
32 M 7Y Y N 171.76 N JE  +ve 
33 F 8Y Y N 255.29 N JE  +ve 
34 F 8Y Y N 277.19 N JE  +ve 
35 M 8.6Y Y N 793.56 N JE  +ve 
36 M 4Y Y N 769 N JE  +ve 
37 M 7Y Y N 11.11 N JE –ve 
38 M 1Y Y N 29.23 N JE –ve 
Table 1. Information sheet of patients (n = 38) with acute encephalitis in Uttar Pradesh (India), 2005. 
 
Saxena et al. - Escalating JE in North India.               J Infect Dev Ctries 2009; 3(7):517-530. 
 
521 
 
 
 
 
 
joining tree was constructed using the ClustalX 
(1.83) alignments program in Phylip (3.68) and 
visualized by Treeview [Win32]  version 1.6.6 
(Figure 2).  
Rigorous steps were taken to avoid risk of 
contamination of samples, or cross-contamination 
between samples. All the epidemiological samples 
were handled separately in a biosafety cabinet hood 
in a BSL3 facility to avoid any lab contamination. 
All RT-PCR and product analysis procedures 
described were independently repeated. Standard 
precautions to avoid product contamination were 
taken for all RT-PCR assays. Reaction mixtures for 
the reverse transcription and PCR stages were 
always prepared in a laminar flow-hood. The 
remainder of aliquots of the PCR master mixes were 
disposed after the first use. In addition to the use of 
non-infected control samples, all steps up to and 
including the analysis of the RT-PCR products were 
physically separated by working in a laboratory that 
did not use related products and all work was 
undertaken with designated equipment. 
 
Analysis of Trend of JE in Uttar Pradesh 
In order to investigate the possible trend of 
occurrence of JE, we compared the 2005 JE  
 
 
 
 
epidemic with the 1978 and 1980 epidemics, and 
also plotted a graph of cases/deaths and year of 
occurrence for 1992-2008. Data in this study was 
obtained from the World Health Organization 
(WHO) [2], National Institute of Communicable 
diseases (NICD) [8], National Vector Borne Disease 
Control Programme (NVBDCP) [9] and Indian 
Council of Medical Research (ICMR) [13]. Graphs 
were plotted between numbers of cases/deaths and 
time. WHO is the international surveillance agency 
and NICD, NVBDCP and ICMR are the Indian 
Government  surveillance agencies that maintain 
such records.  
 
Statistical analysis 
The serological and CSF analysis were 
represented as arithmetic means (A.M.)  SD. The 
data was analyzed using student t-test and 2-test P  
0.05. Rate of infection per million population (RM) 
and relative ratio (RR) was calculated as mentioned 
by Nash et. al. [14]. 
 
Results 
Demographic characteristics 
A demographic investigation of all 38 
 
Figure 2.  Phylogeny of Japanese encephalitis virus GP05 isolated from the Gorakhpur 2005 epidemic, with reference 
to other Southeast Asian isolates and flaviviruses based on partial env gene sequence. The tree was generated by neighbor-
joining method. Bootstrap values are indicated at the branch points. DEN, WNV, KUN, SLEV and MVE denotes Dengue virus, West 
Nile virus, Kunjin virus, Saint Louis encephalitis virus and Murray Valley encephalitis virus respectively. 
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S.N. Virus I.D. Accession No. Country Year of Isolation Host Genotype 
1 691004 Z34097 Sri Lanka 1969 Human III 
2 733913 Z34095 India 1973 Human III 
3 782219 U70402 India 1978b Human III 
4 826309 U70403 India 1982a Human III 
5 7812474 U70387 India 1978c Human III 
6 B2524 U70392 Nepal 1985 Human III 
7 Beijing-1 L48961 China 1949 Human III 
8 Dengue M29095 New Guinea 1944 Human  
9 FU AF217620 Australia 1995 Human II 
10 G8924 U70394 India 1956 Mosquito III 
11 GP-05 FJ979830 India 2005 Human III 
12 GP-14 DQ914531 India 2005 Human III 
13 GP-48 DQ914532 India 2005 Human III 
14 GP-55 DQ914529 India 2005 Human III 
15 GP-67 DQ914530 India 2005 Human III 
16 GP78 AF075723 India 1978 Human III 
17 GP-82 DQ914528 India 2005 Human III 
18 H49778 U70395 Sri Lanka 1987 Human III 
19 JaNAr0102 AY377577 Japan 2002 Mosquito I 
20 014178 EF623987 India 2001 Human III 
21 04940-4 EF623989 India 2002 Mosquito III 
22 057434 EF623988 India 2005 Human III 
23 JKT5441 U70406 Indonesia 1981 Mosquito II 
24 JKT7003 U70408 Indonesia 1981 Mosquito IV 
25 JKT9092 U70409 Indonesia 1981 Mosquito IV 
26 K91P55 U34928 Korea 1991 Mosquito I 
27 Kunjin D00246 Australia 1960 Mosquito  
28 MVE AF161266 Australia 1951 Human  
29 826309 U03689 India 1982b Human III 
30 Nakayama U03694 Japan 1935 Human III 
31 NO L43566 Australia 1995 Human II 
32 P20778 Z34096 India 1958 Human III 
33 R53567 U70418 India NA NA III 
34 SLEV NC_007580 USA 1975 Birds  
35 Usutu NC_006551 Australia 2001 Blackbird  
36 WNV AF206968 Egypt 1950 Human  
Table 2. Sequence information of JEV and other flaviviruses used in phylogenetic study. 
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* Population figures are from the 2001 India Census. 
 
 
 
 
 
 
 
 
S.N Patient group 
No. of 
patients 
(%) 
Population at 
risk (million) 
Population at 
risk (%) 
RM RR 95% CI 
A 
JE ( ve) patients below 
six 
7 18.4 
14.015329 8.4 
0.5 
1.09 0.05-24.9 
JE ( ve) patients below 
six 
5 13.2 0.36 
JE ( ve) patient above 6 14 36.8 
60.929021 36.7 
0.23 
JE ( ve) patient above 6 12 31.6 0.2 
 
B 
JE ( ve) female patient 
below 6 
1 2.6 
6.771362 4.1 
0.15 
0.62 0.01-67.1 
JE ( ve) female patient 
below 6 
2 5.3 0.3 
JE ( ve) female patient 
above 6 
7 18.4 
29.059214 17.5 
0.24 
JE ( ve) female Patient 
above 6 
6 13.2 0.21 
 
C 
JE ( ve) male patient 
below 6 
6 18.4 
7.243967 4.4 
0.83 
1.24 0.78-1.97 
JE ( ve) male patient 
below 6 
3 7.9 0.41 
JE ( ve) male patient 
above 6 
7 18.4 
31.869807 19.2 
0.22 
JE ( ve) male patient 
above 6 
6 15.8 0.19 
 
D 
Total JE ( ve) female 
patient 
8 21.1 
35.830576 21.6 
0.22 
0.85 0.02-37.5 
Total JE ( ve) female 
patient 
8 21.1 0.22 
Total JE ( ve) male 
patient 
13 34.2 
39.113774 23.5 
0.33 
Total JE ( ve) male 
patient 
9 23.7 0.23 
 
E 
JE ( ve) male patient 
below six 
6 15.8 
6.771362 4.1 
0.89 
2 0.1-55.7 
JE ( ve) male patient 
below six 
3 7.9 0.44 
JE ( ve) female patient 
below six 
1 2.6 
7.243967 4.4 
0.14 
JE ( ve) female patient 
below six 
2 5.3 0.28 
 Total population of U.P. * 166197921 
Table 3. Demographic characteristics of patients (n = 38) with acute encephalitis in Uttar Pradesh (India), 2005. 
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encephalitis patients was conducted and the 
population attack rate was calculated. Our study 
shows that the disease affected predominantly the 
low socio-economic, rural children aged 3 months to 
15 years, in far-flung paddy fields, with a male to 
female ratio of 1.63:1. Estimated population at risk 
was 45.1% in the endemic areas. As per the 2001 
census, the patients were classified into two groups 
(below and above six years of age) and RM and RR 
were calculated as presented in Table 3. RM 
suggests that patients below six years of age were 
more prone (RM 0.5) than patients above age six 
(RM 0.23). Males (RM 0.83) were found to be 
almost six times more susceptible to encephalitis 
than females (RM 0.15) below age six. Females 
above six years of age (RM 0.24) were more 
susceptible to JEV infection than females aged six or 
younger (RM 0.15). Data suggest that all patients 
and males below six years of age were more  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
susceptible to JE infection, and males were more 
susceptible than females. The demographic features 
of encephalitis patients were consistent with JEV 
infection.  
 
Clinical characteristics 
This study suggests that acute encephalitis was 
marked by high-grade fever (100%), altered 
sensorium (100%), headache (71.4%), stiffness of 
the neck (47.6%), tremors (81%), vomiting (57.1%), 
altered mental status (47.6%), seizure (76%), 
myalgia (19%), abdominal pain (19%), depressed 
level of consciousness with coma, and paralysis 
followed by death. 76% patients suffered slurred 
speech (Table 4). Notably, the patients who survived 
showed evidence of mental retardation and/or 
neurological deficit. The clinical symptoms are 
suggestive of JEV infection among 21 patients out 
of 38 patients diagnosed as encephalitis.  
 
Figure 3.  Occurrence of Japanese encephalitis in Uttar Pradesh, India, in   
Presentation of cases (epidemic curve) of acute encephalitis in the 2005 epidemic. The graph represents the total 
 ) reported during the acute encephalitis epidemic in 2005 in eastern Uttar Pradesh. (b) 
 
together suggest an increase in the number of patients ( , early occurrence (  and early shift in peak (  as in 2005 
encephalitis started in late July and the peak (n = 2,554) timing of the epidemic was mid-September, while in 1980 
encephalitis started in early September and the peak (n = 56) timing of the epidemic was early October, and in 1978 
the epidemic started in late September and peaked (n = 55) in late October. (Values from ref. 2,7,13). 
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The pathological investigations revealed that out 
of 38 cases, 55.3% (n=21) samples were positive for 
JE  (Table 1) when tested by rapid IgM capture 
ELISA (JEV CheX) as described in materials and 
methods. Notably, during the epidemic of 2005, 
WHO reported only 37% cases of encephalitis were 
JE positive, which includes clinical as well as 
laboratory confirmed cases both [2]. A serological 
finding of our study is presented in Table 5. The 
infection could be characterized by marked 
pleocytosis in cerebrospinal fluid (90  76.9 
cells/cubic mm), and peripheral leucocytosis (64.7  
8.86% neutrophils) with mild anaemia (hemoglobin; 
11.2 ± 3.25 g/dL). The data also exhibit alteration in 
lymphocyte (28.9 ± 8.4%) and polymorph (64.7 ± 
8.86%). No significant difference was observed in 
white blood cell count (8416.7 ± 1192.6 cells/ L), 
eosinophil (1.95 ± 0.67%), reticulocyte count (1.92 
± 0.56%) and blood glucose (95.4 ± 25.1mg/dL). 
The CSF was collected within 2 to 7 days (4.2 ± 
1.36 days) of onset of disease. Shifting of CSF 
protein content (49.5 ± 30.1mg/dL) towards the 
upper side of normal range (20.0-50.0 mg/dL) was 
also observed. Mild anaemia and leucocytosis with 
neutrophilia is one of the symptoms of JE infection. 
All the 21 cases, which were found JE positive by 
pathological investigations, were also confirmed to 
be JE positive by the serological investigation (Table 
5). 
 
 
Phylogenetic analysis of GP05 
The 2005 encephalitis epidemic surpassed all the 
pervious epidemics in its intensity; therefore, we 
sequenced GP05 and performed phylogenetic 
analysis. Our results (shown in Figure 2) suggest 
that the circulating strain GP05 was close to GP78 
(the known endemic strain isolated in 1978) [7], and 
all the Indian JEV strains clustered together and fell 
in Genotype-III.  The phylogenetic tree also 
proposes that the JEV strain 057434 isolated in 2005 
from Gorakhpur (Uttar Pradesh), and 04940-4 
isolated in 2002 from Bhandara (Maharashtra), are 
close to GP05. However, the JEV strain 014178 
isolated in 2001 from Lakhimpur (Uttar Pradesh), is 
distinct from all the above-mentioned strains and lies 
between other 2005 strains and GP05.  
 
Trend of JE occurrence 
Since its first detection in India in 1955, JE has 
shown an increasing trend in its occurrence; 
however, it was not reported in Uttar Pradesh until 
1978. There were two epidemics back to back in 
Uttar Pradesh in 1978 and 1980 preceded by heavy 
rainfall. We further compared the 2005 epidemic 
with the previous epidemics of 1978 and 1980 to 
predict the trend of JE epidemics in the area. In 
2005, the encephalitis outbreak started in late July 
and peaked (n = 2,554) in mid-September, while in  
 
Clinical Characteristics No. of Patients (%) 
  
Syndromes     
Encephalitis     
With weakness 7 33 
Without weakness 6 28.6 
Aseptic meningitis without encephalitis 6 28.6 
Fever and headache 15 71.4 
 
Signs and symptoms     
Fever (temperature > 37.8) 21 100 
Weakness 15 71.4 
Vomiting 12 57.1 
Headache 15 71.4 
Altered mental status 10 47.6 
Stiff Neck 10 47.6 
Myalgia 4 19 
Tremor 17 81 
Slurred speech 16 76 
Abdominal pain 4 19 
Seizures 16 76 
Altered sensorium 21 100 
Table 4. Presentation of clinical features in patients (n = 21) with Japanese encephalitis in Uttar Pradesh (India), 2005. 
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1980 encephalitis started in early September and 
then peaked (n = 56) in early October. In 1978 the 
epidemic started at late September and peaked (n = 
55) in late October (Figure 3).  These data indicate a 
significant increase in the number of patients, early 
occurrence (September to July), and early shift in 
peak timing (October to September). The duration of  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
the infection has also increased from four months to 
five months (Figure 3).  
During 1955 to 1965, a total of 52 cases were 
reported in India. During 1966 to 1975, reported 
cases numbered 763 with 325 deaths, whereas in 
1976 to 1985 more than 8,000 cases with 2,600 
deaths were reported in India [13]. To obtain more 
information about the infection pattern of JE, we 
Figure 4. Emerging trend of Japanese encephalitis in Uttar Pradesh between 1992-2008, including (A) and 
excluding (B) the 2005 epidemic. The graph represents yearly total number of JE cases reported ( ), total 
number of deaths ( ), trend lines for total number of cases (-----) and deaths ( ). (Values from ref. 2,8,9). 
 
 A 
B 
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plotted a graph (Figure 4A) for the total number of 
JE cases/deaths in Uttar Pradesh for seventeen years 
(1992-2008) based on the numerical values available 
from NICD and NVBDCP. Our results (presented in 
Figure 4A) suggest that JE in North India is 
escalating and larger epidemics may occur in the 
future.  We found a similar trend even when we 
excluded data from the 2005 epidemic (Figure 4B). 
 
Discussion 
Since the mid-1950s, JEV activity has been 
reported in various parts of India, both in the form of 
outbreaks of encephalitis and the level of antibodies 
found in the population [7, 15]. JEV, a flavivirus, is  
 
 
 
 
the major cause of encephalitis in Southeast Asia, 
including India, with high mortality. Among all viral 
encephalitis that is encountered in India, JE appears 
to be of greater significance. Only one of every 300 
persons infected with JEV develops clinical 
encephalitis. The mortality in this disease has varied 
from 20-40% in different parts of India. The 
majority of the deaths occur during the first week of 
illness. A deadly outbreak of undiagnosed brain 
fever was reported in Uttar Pradesh and adjoining 
areas during 2005. In intensity and magnitude, it 
surpassed all the previously reported epidemics.  
Our pathological investigations revealed marked 
pleocytosis in cerebrospinal fluid and peripheral 
leucocytosis with mild anaemia, which is in 
accordance with earlier studies done by Kumar et al. 
[16] in the same area. In CSF the elevated level of 
cells and alteration of protein level indicates 
penetration of the blood-brain barrier. The migration  
of neutrophils at the site of injury may be attributed 
to the production of soluble macrophage-derived 
factor (MDF), which is one of the key mediators in 
the host-innate immune response during JEV 
infection [17]. The mild anaemia may be because a 
result of MDF-induced hyperferretimia in serum 
[18]. The malfunctioning of the liver and kidney 
reported by Kumar et al. [16], may be caused by 
replication of the virus in these organs [19]. 
Presence of virus in CSF from most of the fatal 
cases might suggest that the virus is actively 
multiplying in the central nervous system. This also  
 
 
 
 
 
 
suggests that virus isolation or demonstration of CSF 
is an indicator of poor prognosis because some of 
the patients with low levels of IgM antibodies in 
CSF/serum expired. The present findings are 
comparable to the previous reports that isolation of 
virus from CSF and low levels of JEV-specific IgG 
and IgM in CSF and serum correlated significantly 
with mortality [16]. 
Our demographic, clinical, pathological, and 
serological investigations confirm the circulation of 
JEV in Gorakhpur and adjoining areas. We have 
earlier reported the prevalence of JEV-GP78 in the 
affected area [7] and our present results (Figure 2) 
reconfirm the presence of GP78 in North India, 
especially in Uttar Pradesh during the JE outbreak of 
2005. Clustering of JEV strains GP05 and 057434 
(reported from another laboratory during the same 
epidemic) with GP78 again concurs with our results 
and also suggests that identification of GP05 by RT-
Variable Mean  SD Range Normal Range 
Blood 
White -cell count (cells/ L) 8416.7  1192.6 6300 11000 3530 13050 
Hemoglobin (g/dL) 11.2  3.25 6.0 17.5 11.5 18.0 
Lymphocyte (%) 28.9  8.4 13.0 43.0 25.0 50.0 
Polymorph (%) 64.7  8.86 50.0 83.0 30.0 60.0 
Eosinophil (%) 1.95  0.67 1.0 3.0 0.3 5.0 
Reticulocyte Count (%) 1.92  0.56 1.0 3.0 1.0 2.0 
Blood glucose (mg/dL) 95.4  25.1 60.0 140.0 70.0 140.0 
Cerebrospinal fluid 
Interval between onset and 
collection (days) 
4.2  1.36 2 7  
Cell count (per mm3) 90  76.9 10.0 260.0 < 4.0 
Protein (mg/dL) 49.5  30.1 20.0 100.0 20.0  50.0 
Glucose (mg/dL) 50.57  9.4 36.0 68.0 40.0 70.0 
Table 5. Laboratory results of patients (n = 21) with Japanese encephalitis in Uttar Pradesh (India), 2005. 
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PCR is real positivity and not laboratory 
contamination during the PCR procedure. JEV strain 
014178, isolated in 2001 from Lakhimpur (Uttar 
Pradesh), caused high fatality in pediatrics claiming 
443 cases with 96 deaths (CFR 21.7%) [20]. 
Therefore, it appears that further evolution of the 
2001 strain may have caused the large JE outbreak 
of 2005 with high fatality (CFR 22.9%). Similarly, 
JEV strains 057434 and 04940-4 caused high fatality 
and were also found to be closely associated with 
GP05. Few JEV strains isolated from the same 
epidemic differ from GP05 [21]. This may have two 
possible explanations: (i) the co-circulation of JEV 
GP05 with other already circulating strains in the 
area, and (ii) the lack of proofreading activity of 
viral RNA dependent RNA polymerase leading to a 
mutation in viral genome during RNA replication 
resulting in diverse evolution of 2001 JEV strain 
(014178). If this is the case, the possibility of further 
evolution/emergence of new JEV strains cannot be 
excluded. The presence of JEV strain 04940-4 in 
Bhandara, (Maharashtra State) in 2002 suggests that 
JE is spreading to new areas, which is an alarming 
concern.  
 Considering the large number of JE negative 
results, it is important to understand that different 
diseases of children affecting the brain and 
sensorium and causing death should not be clubbed 
together just because they occurred in the same time 
period, assuming that all of them represented one 
epidemic. There were a few cases with low platelet 
counts with fever. This clinical picture was clearly 
different from JE, and was most probably due to 
Dengue [3,16]. Earlier studies have shown that in 
addition to JEV few other serologically related 
flaviviruses, such as Dengue and West Nile viruses, 
are active in Uttar Pradesh [7]. Another reason for 
the large number of non-JE patients may be the low 
level of viremia and rapid development of 
neutralizing antibody. It is very difficult to detect 
genomic RNA or to isolate virus from serum 
samples; hence IgM capture ELISA for JE antibody 
or reverse transcription after virus culture are 
recommended [21,22,23]. However, cross-reactivity 
of antibody and mutation during culture passage and 
reverse transcription are the main drawbacks.  These 
difficulties also emphasize the need for CSF 
collection for epidemiological studies and clinical 
diagnosis. Consequently, there is a need for effective 
and efficient methods for diagnosis and 
identification of JEV in patients.  
Commencing in the last week of July, the 2005 
encephalitis epidemic started about a month earlier 
as compared to the previous epidemics of 1978 and 
1980 (Figure 3). The early detection of JE could be 
attributed to the improved surveillance/diagnoses, 
but ecological issues such as seasonal drift also need 
consideration. Even though the data points for the 
1978 and 1980 epidemics are far less in comparison 
to the 2005 epidemic, the graph suggests that further 
investigation in the future will help us to understand 
JE circulation kinetics for better management during 
future epidemics. Interestingly, our graph (Figures 
4A and 4B) suggests an escalating trend of JE year 
by year in Uttar Pradesh and indicates that there 
might be an even larger JE epidemic in the future. 
This observation is in accordance with a recent 
prediction of substantial risk of zoonotic and vector-
borne emerging infectious diseases (such as JE) in 
North India, especially in Uttar Pradesh and 
adjoining areas [24]. Deeper insights are required to 
determine why JE is showing an intensifying trend 
in North India. The affected area in North India is 
known as the “Terai area.” Floods are an annual 
feature in the region giving rise to water logging. 
The warm, humid climate of the region provides an 
excellent breeding ground for Culex 
tritaeniorrhynchus and Culex vishnui mosquitoes, 
which are vectors of JE. Therefore, during the rainy 
season, an increase in the population density of the 
mosquito in this division is observed.  The area is 
densely populated so mosquito-human contact is 
very frequent. Villages in this rice-growing region 
abound in stray and reared pigs. Studies from 
peninsular and eastern parts of India indicate that 
pigs are the main vertebrate host of the virus and the 
major reservoir of the infection [25]. Pigs, besides 
other animals, are widely prevalent in both rural and 
urban areas of Uttar Pradesh. However, 
epidemiological and ecological aspects of the illness 
are yet to be studied in this part of the country.  Due 
to the evolution of new viral strains and/or 
reemergence of older viral strains, children lack herd 
immunity. Although health management facilities 
are improved in the area, there is still a lack of 
adequate resources and proper facilities for health 
care and hygiene. These factors may be the 
responsible for the intensifying trend of JE in North 
India. 
JE is still a major health problem in North India. 
No proper antiviral against JEV is available 
[26,27,28]. The following preventive measures may 
largely mitigate the disease: proper sample 
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collection; prediction of future strain(s); educating 
public health workers and professionals; 
vaccination; trials of new antiviral therapy; 
improvement in clinical management, especially 
early and specific detection; nutritional support to 
the affected patients. Wider issues, including current 
agricultural practices, water management systems, 
and human behavioral patterns, need to be 
investigated. Alterations in ecological issues such as 
seasonal drift, which may cause shifts in the early 
occurrence of the disease, should also be taken into 
consideration. There is a need to monitor JE in birds, 
mammals and its vector(s), along with human, to 
obtain the proper information about climatic, 
entomological, viral, and human host factors 
affecting JE. The remedy lies in tackling the cause 
and there is a need for a joint venture among health 
officials, researchers, clinicians and ecologists who 
can save lives by resolving the causative factors and 
solve the escalating problem of JE in India. To this 
end, a combination of strategies is required and we 
need to proceed with a sense of urgency in this 
matter. 
Our results show that JEV infection led to 
marked pleocytosis in CSF and peripheral 
leucocytosis with mild anemia.  All the JEV strains 
reported in India fall under Genotype III.  The JEV 
strain circulating during 2005 was similar to GP78 
and possibly originated due to the diverse evolution 
of the 2001 JEV strain. JE is also spreading to newer 
areas. The trend of JE suggested that the problem in 
North India is escalating and larger epidemics may 
occur in the future.  Considering the possibility of a 
larger epidemic in the future, serious steps should be 
taken to combat JE, including the development of 
more efficient surveillance methods and differential 
diagnosis.  
 
 
Gene Accession Number 
The sequencing result leads to identification of 1524 
bp ss-RNA (JEV GP05 envelope gene), which was 
submitted in NCBI with FJ979830 accession number. 
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